CN117355322A - 人源化mAb107 - Google Patents

人源化mAb107 Download PDF

Info

Publication number
CN117355322A
CN117355322A CN202280037583.8A CN202280037583A CN117355322A CN 117355322 A CN117355322 A CN 117355322A CN 202280037583 A CN202280037583 A CN 202280037583A CN 117355322 A CN117355322 A CN 117355322A
Authority
CN
China
Prior art keywords
ser
antibody
antigen
seq
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037583.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·阿尔瑙特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN117355322A publication Critical patent/CN117355322A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280037583.8A 2021-03-26 2022-03-25 人源化mAb107 Pending CN117355322A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166711P 2021-03-26 2021-03-26
US63/166,711 2021-03-26
PCT/US2022/021950 WO2022204516A1 (en) 2021-03-26 2022-03-25 Humanized mab107

Publications (1)

Publication Number Publication Date
CN117355322A true CN117355322A (zh) 2024-01-05

Family

ID=83397925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037583.8A Pending CN117355322A (zh) 2021-03-26 2022-03-25 人源化mAb107

Country Status (7)

Country Link
US (1) US20240158511A1 (https=)
EP (1) EP4313112A4 (https=)
JP (1) JP2024511160A (https=)
CN (1) CN117355322A (https=)
AU (1) AU2022243562A1 (https=)
CA (1) CA3214962A1 (https=)
WO (1) WO2022204516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026511370A (ja) * 2023-02-27 2026-04-14 カイジーン，インク． ヒト化抗ｃｄ１１ｂ抗体およびその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1461310A (zh) * 2000-02-10 2003-12-10 艾博特公司 结合人白介素－18的抗体及制备和使用方法
WO2016138538A2 (en) * 2015-02-27 2016-09-01 The General Hospital Corporation Therapeutic use of integrin-binding antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107750255B (zh) * 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1461310A (zh) * 2000-02-10 2003-12-10 艾博特公司 结合人白介素－18的抗体及制备和使用方法
WO2016138538A2 (en) * 2015-02-27 2016-09-01 The General Hospital Corporation Therapeutic use of integrin-binding antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABBAS DEHNADI等: "Prophylactic orthosteric inhibition of leukocyte integrin CD11b/CD18 prevents long-term fibrotic kidney failure in cynomolgus monkeys", NATURE COMMUNICATION, 10 January 2017 (2017-01-10), pages 1 - 11 *

Also Published As

Publication number Publication date
AU2022243562A1 (en) 2023-10-12
US20240158511A1 (en) 2024-05-16
WO2022204516A1 (en) 2022-09-29
AU2022243562A9 (en) 2024-02-22
JP2024511160A (ja) 2024-03-12
EP4313112A1 (en) 2024-02-07
EP4313112A4 (en) 2025-07-02
CA3214962A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
EP2766044B1 (en) Treatment of ocular disease
ES2404941T3 (es) Anticuerpos anti-miostatina
ES2533464T3 (es) Anticuerpos anti-miostatina
US10179821B2 (en) Anti-factor D antibodies
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
CN102459333A (zh) 抗-Tau pS422抗体用于治疗脑病的应用
JP2010528607A (ja) スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合性タンパク質
US10961313B2 (en) Anti-factor D antibody variant conjugates and uses thereof
KR20210071987A (ko) 항-cd79 항체 및 이들의 용도
CN117355322A (zh) 人源化mAb107
JP2024546183A (ja) 抗ｃ３抗体及びその抗原結合性断片並びに眼科疾患又は眼疾患を処置するためのそれらの使用
US12540187B2 (en) Method of treating vascular eye and retinal diseases by administration of anti-Neuropilin 1A antibodies
WO2020022438A1 (ja) 網膜線維化を伴う眼疾患の処置剤
WO2025119330A1 (zh) 氨基酸接头结合分子及其用途
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
HK1230624A1 (en) Anti-factor d antibody variants and uses thereof
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination